Medically Reviewed By
Dr. Aditya Singh, MBBS, MD (Pharmacology)
Reg No: MCI-654321 • Verified Medical Reviewer
Kisplyx
(lenvatinib)
Uses, side effects, dosage information & price range
About this medicine
Kisplyx is indicated for the treatment of adults with advanced renal cell carcinoma (RCC): in combination with pembrolizumab, as first-line treatment (see section 5.1). in combination with everolimus, following one prior vascular endothelial growth factor (VEGF)-targeted therapy.
Common Brand Names for this Composition
The following popular commercial brand names contain lenvatinib as their active ingredient composition:
Lenvima 4mg Capsule
Eisai Pharmaceuticals India Pvt Ltd
Lenvima 10mg Capsule
Eisai Pharmaceuticals India Pvt Ltd
Kisplyx
Eisai GmbH
Lenvima
Eisai GmbH
Common Substitutes & Alternatives
These medicines share the same salt composition or therapeutic category and can be used as substitutes under professional medical supervision.
Key Information
Salt / Composition
lenvatinib
Category
Antineoplastic agents
Manufacturer
Eisai GmbH
Medical Disclaimer
This information is for educational purposes only and is not a substitute for professional medical advice. Always consult your doctor or pharmacist before taking any medication. Prices are indicative and may vary. Do not start, stop, or change the dosage of any medicine without your doctor's approval.
Disclaimer:Content on this page is for informational purposes only. Do not consume prescription medication without a registered practitioner's direct oversight.